home / stock / nm:cc / nm:cc news

NM:CC News and Press, Novamind Inc.

Stock Information
Company Name: Novamind Inc.
Stock Symbol: NM:CC
Market: CNQC
Website: novamind.ca/
Menu
NM:CC NM:CC Quote NM:CC Short NM:CC News NM:CC Articles NM:CC Message Board
Get NM:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
NM:CC - Medical Insurance Providers Assess Benefits of Psychedelics Treatments

While it is still unknown whether insurance will pay for psychedelics-based mental health treatment, there is some evidence that providers are at least looking for more data on the therapy. Two years ago, the Multidisciplinary Association of Psychedelic Studies (MAPS) worked with Elliot M...
NM:CC - CSE Bulletin: Delist -Novamind Inc. (NM)

Toronto, Ontario--(Newsfile Corp. - le 13 juin/June 2022) -  Novamind Inc. (“Novamind” or the “Company”), has announced that the Company has completed its previously announced acquisition by Numinus Wellness Inc . by way of a plan of arrangemen...

NM:CC - Novamind Obtains Final Order for Plan of Arrangement from the Supreme Court of British Columbia and Completes Acquisition by Numinus Wellness Inc.

TORONTO, ON / ACCESSWIRE / June 10, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that the Company has completed its previously announced acquisition by Numinus Welln...

NM:CC - Novamind Shareholders Approve Proposed Acquisition by Numinus

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Numinus shareholders, at a separate meeting held today, have also approved the resolutions related t...
NM:CC - Novamind Announces New Patient Financing Options

TORONTO, ON / ACCESSWIRE / June 2, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced new patient financing options to help patients access critical mental healthcare servic...

NM:CC - Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights

Record high quarterly revenue of $3,227,352, +32% over the previous quarter Growth driven by Arizona acquisition, expanding clinic network to eight total locations Numinus to acquire Novamind, creating a preeminent North American platform, spanning 13 wellness clinics, four resear...

NM:CC - Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders of Novamind Vote FOR the Proposed Plan of Arrangement

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. TORONTO, ON / ACCESSWIRE / May 27, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"...
NM:CC - Novamind Launches Group Psychedelic Treatment for Frontline Workers

Following successful clinical pilot, treatment becomes regular offering at Novamind clinics TORONTO, ON / ACCESSWIRE / May 19, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, toda...

NM:CC - Novamind Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Court Order for Plan of Arrangement

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Shareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 a...

NM:CC - Novamind to Host Bionomics' PREVAIL Trial for Acute Treatment of Social Anxiety Disorder

TORONTO, ON / ACCESSWIRE / May 10, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinical trial for the acute treatment of social anxiet...
Next 10